# FDA/FTC Compliance Software for Regenerative Medicine Clinics - RegenCompliance

Purpose-built compliance scanning for stem cell, PRP, and exosome clinics. The regen-medicine rule set - built from the FDA warning letters and FTC settlements that have shaped enforcement in this space.

Canonical page: https://regencompliance.ai/for/regen-clinics


## Risk summary

Regenerative medicine is the specialty that shaped much of today's FDA enforcement on healthcare marketing. FTC settlements over social-media stem cell claims, the Kimera Labs exosome case, and ongoing FDA CBER attention on HCT/P products have each set precedent for how every regen clinic's marketing is read. Our rule set started with this specialty, and we built it first for regen clinics.


## Real enforcement examples

- **FTC and state actions over social-media stem cell claims**: The FTC and state attorneys general have taken action against stem cell clinics over social-media claims that treatments could cure arthritis, heal spinal cord injury, or reverse aging. Outcomes in this area have included refunds to patients, long-term compliance monitoring, and orders to stop repeating the claims. A single post can be enough to start an investigation.
- **FDA warning letters on 'FDA-approved stem cell' language**: The FDA has issued a sustained campaign of warning letters on language implying FDA approval of HCT/P products. 'FDA-approved stem cells,' 'FDA-approved treatment,' and variations remain among the most-cited phrases in active enforcement.
- **FDA CBER actions on HCT/P marketing outside the 361 pathway**: HCT/P products are regulated under CBER with a specific pathway for minimal-manipulation, homologous-use products. Marketing products outside this pathway as 'minimally manipulated' or 'homologous use' - or making therapeutic claims that push the product into the 351 (drug/biologic) pathway - has produced warning letters to clinics and lab partners.
- **FTC actions on exosome marketing**: Exosome marketing has drawn particular FTC attention. Claims that exosomes 'repair,' 'regenerate,' or 'heal' tissue - standard language in exosome marketing a few years ago - are now specific enforcement targets.
- **State AG actions on regen clinic consumer protection**: Beyond FDA and FTC, state Attorneys General have used consumer protection authority to pursue regen clinics. Texas, California, and New York have each brought actions based on the intersection of state consumer protection and healthcare marketing.


## High-risk phrases and compliant alternatives

- **"FDA-approved stem cells"** (HIGH risk): Most HCT/P products are not FDA-approved. The phrase is the single most-cited in regen enforcement.
  - Compliant alternative: "Performed in an FDA-registered facility using HCT/P materials under the 361 pathway"
- **"Cures arthritis"** (HIGH risk): Disease cure claim - direct FDA enforcement target going back to the 2010s.
  - Compliant alternative: "May support joint comfort and function for some patients"
- **"Heals damaged tissue"** (HIGH risk): Therapeutic efficacy claim that pushes product into drug-regulatory pathway.
  - Compliant alternative: "Some patients report improvement in function and comfort in the treated area"
- **"Reverses aging"** (HIGH risk): An active FTC enforcement target in stem cell marketing.
  - Compliant alternative: "May support aspects of skin and tissue health in the treated area"
- **"Guaranteed results"** (HIGH risk): Guarantee claim is almost never substantiable for regenerative therapies.
  - Compliant alternative: "Outcomes vary; we discuss realistic expectations during every consultation"
- **"Proven to regrow cartilage"** (HIGH risk): Tissue regeneration claim subject to FDA CBER scrutiny and FTC substantiation rules.
  - Compliant alternative: "Clinical studies on [specific protocol] have shown [specific endpoint]; patient outcomes vary"
- **"Exosomes repair damaged cells"** (HIGH risk): Current FTC target; 'repair' claims on exosomes are under active enforcement.
  - Compliant alternative: "Research into exosome biology continues; our current protocols use [product] for [appropriate indication]"
- **"100% safe, no side effects"** (HIGH risk): Absolute safety claim conflicts with clinical reality and substantiation rules.
  - Compliant alternative: "Adverse events are rare but possible; candidacy and risks are discussed at consultation"
- **"Alternative to surgery"** (MEDIUM risk): Comparative claim implies equivalence to surgical outcomes without substantiation.
  - Compliant alternative: "A non-surgical option some patients choose to explore before considering surgery"
- **"Works for all patients"** (HIGH risk): Universal efficacy claim is not substantiable for any regenerative protocol.
  - Compliant alternative: "May be appropriate for patients who meet specific candidacy criteria discussed at consultation"
- **"Treats spinal cord injury"** (HIGH risk): Direct disease/condition treatment claim on HCT/P products is an FDA target.
  - Compliant alternative: "(Remove entirely - no compliant reframe for direct spinal-cord-injury treatment claims)"
- **"Breakthrough therapy"** (MEDIUM risk): 'Breakthrough therapy' is a specific FDA designation; misuse is a direct flag.
  - Compliant alternative: "An emerging area of regenerative treatment we are offering based on current evidence"


## Common mistakes

- **"FDA-approved stem cells"** (FDA HCT/P pathway (21 CFR 1271)): Almost no stem cell product on the consumer market is FDA-approved. Most operate under the 361 pathway, which does not require pre-market approval. Calling them 'approved' is the single most-cited regen enforcement pattern. RegenCompliance rewrites to 'performed in an FDA-registered facility using HCT/P materials under the 361 pathway.'
- **"Cures arthritis"** (FDA disease-claim rule (21 USC 321(g))): 'Cure' on a recognized disease state like arthritis pushes your HCT/P offering out of the 361 pathway and into the 351 (drug/biologic) pathway, which requires full FDA approval you do not have. We catch every disease-cure variant and rewrite to 'may support joint comfort and function.'
- **"Heals damaged tissue"** (FDA HCT/P 361 vs 351 pathway distinction (21 CFR 1271.10)): Therapeutic 'heal,' 'repair,' and 'regenerate' claims signal you are operating outside 361's homologous-use requirement. The FDA reads this language as evidence the product should be regulated as a drug. We flag therapeutic claim patterns and rewrite to functional improvement framing.
- **"Reverses aging"** (FTC Section 5 (substantiation)): The FTC treats 'reverses aging' on stem cell services as a clear enforcement target. We flag every age-reversal variant and rewrite to a 'may support aspects of skin and tissue health' framing.
- **"Exosomes repair damaged cells"** (FTC substantiation under Section 5 (current enforcement priority)): Exosome 'repair' marketing is a current FTC focus. Claims that exosomes repair, regenerate, or heal lack the competent-and-reliable scientific evidence the FTC requires. We rewrite to 'research into exosome biology continues; our protocols use [product] for [appropriate indication].'
- **"Treats spinal cord injury"** (FDA disease-treatment claim (21 USC 321(g)), CBER scrutiny): Spinal cord injury treatment claims on HCT/P products are a direct disease-treatment claim and continue to draw FDA CBER attention. There is no lower-risk reframing - we flag the phrase pattern and recommend complete removal.
- **"Proven to regrow cartilage"** (FTC substantiation (15 USC 45) + FDA tissue-regeneration claim): Tissue regeneration claims need study-level evidence the FTC reads as competent. They also push HCT/P products toward the drug pathway. We rewrite to study-citation language: 'clinical studies on [protocol] have shown [endpoint].'
- **"100% safe, no side effects"** (FTC absolute-claim substantiation, FDA misbranding): Absolute safety claims are unsubstantiable on any medical procedure. We rewrite to 'adverse events are rare but possible; candidacy and risks are discussed at consultation.'
- **"Alternative to surgery"** (FTC comparative-claim substantiation): Comparative claims to surgical outcomes need head-to-head clinical evidence that essentially never exists for regen vs surgery. We rewrite to 'a non-surgical option some patients choose to explore before considering surgery.'
- **"Breakthrough therapy"** (FDA Breakthrough Therapy designation (FDASIA Section 902)): 'Breakthrough Therapy' is a specific FDA program designation almost no regen clinic actually has. Using it as marketing copy is direct misbranding. We flag the designation language and rewrite to 'an emerging area of regenerative treatment we are offering based on current evidence.'


## What the scanner catches

- **Stem cell service page claims beyond the 361 pathway**: Many regen clinic service pages describe treatments using language that would push the product into the 351 (drug/biologic) pathway. Our scanner is specifically trained on the pathway distinctions - it flags language that implies the regulatory category you are not operating under.
- **Testimonials describing disease-specific outcomes**: Testimonials that name specific conditions ('my arthritis is gone,' 'I can walk again after my stem cell treatment') carry the disease claim into your marketing via the endorsement. Our scanner catches this pattern - which is what triggered several recent enforcement actions.
- **Social media content from staff personal accounts**: Staff personal accounts reposting clinic outcomes, partner content, or general regen marketing often contain language that the clinic's main website has already been cleaned up to avoid. Regulators do not distinguish between the clinic's official account and a physician's personal one.
- **Content partnerships with equipment or biologic suppliers**: Supplier-provided marketing assets (typically written for clinician education rather than consumer marketing) frequently contain language that the supplier itself would not use in consumer-facing channels. Our scanner catches reused supplier content with the specific problem phrases.
- **Conference or webinar recordings posted publicly**: Internal-audience or clinician-audience content (conferences, CE-credit talks, peer presentations) uses a different standard than consumer marketing. Posting these recordings publicly without review often puts clinical-discussion language into a consumer-marketing surface, which is where compliance issues enter.


## Case study: A typical first scan on a regenerative medicine clinic homepage

Before: Our revolutionary stem cell therapy cures arthritis and heals damaged tissue using FDA-approved stem cells. Exosomes repair damaged cells with 100% safe, no side effects - guaranteed results to regrow cartilage and reverse aging. Works for all patients - a proven alternative to surgery for spinal cord injury, joint pain, and chronic conditions.

After: Our regenerative medicine offerings are performed in an FDA-registered facility using HCT/P materials under the 361 pathway. Some patients report improvement in joint comfort and function in the treated area; outcomes vary and candidacy is discussed during every consultation. Adverse events are rare but possible and are reviewed at consultation. A non-surgical option some patients choose to explore before considering surgery. Clinical studies continue to inform our protocols; results depend on many factors specific to each patient.

Outcome: Score went from 8 to 89 across 14 flagged phrases. PDF audit trail generated covering every rewrite. Every core service offering preserved - language reframed to match the 361 regulatory pathway and current FTC enforcement patterns.


## Who this is for

- Stem cell and HCT/P regenerative clinics
- PRP injection practices
- Exosome therapy clinics
- Bone marrow concentrate (BMC) specialists
- Amniotic and placental tissue providers
- Orthobiologics-focused sports medicine and orthopedic practices
- Integrative/functional regen practices
- Regenerative medicine educational businesses


## FAQ

### What is the 361 vs 351 regulatory pathway?

Under FDA rules, HCT/P products that meet specific criteria (minimal manipulation, homologous use, no systemic effect, and a few others) fall under the 361 pathway, which does not require FDA pre-market approval. Products that fail any criterion fall under the 351 pathway, which regulates them as drugs or biologics requiring full approval. Your marketing language signals which pathway you are operating under - and claims appropriate for 351 products (treating specific diseases, systemic effects) are often what trigger enforcement on 361-pathway clinics.

### Does the scanner understand 361 vs 351 distinctions?

Yes. This is one of the specific distinctions our rule set models. Language that implies you are treating a disease, achieving systemic effects, or operating with FDA approval is flagged specifically because it signals the wrong pathway. The lower-risk alternatives are written to match 361-pathway reality while preserving your ability to communicate meaningful patient benefit.

### What about exosome marketing?

Exosomes are a current FTC enforcement priority. The scanner is trained on the specific exosome claims under active enforcement - 'repair,' 'regenerate,' 'heal,' 'restore,' and the combinations that have generated FTC action. Lower-risk alternatives preserve scientific accuracy while avoiding the specific claim patterns.

### Can I still discuss clinical studies in my marketing?

Yes, with accuracy about what the studies actually show. 'Clinical studies on [protocol] in patients with [condition] have shown [specific endpoint]' is much lower-risk when accurate. 'Proven to work,' 'clinically proven,' and similar shorthand is not - our scanner catches the shorthand and suggests a more accurate framing.

### How do I handle testimonials with disease-specific outcomes?

The safest approach: do not publish testimonials that name specific diseases or conditions, even from willing patients. The testimonial carries the disease claim into your marketing regardless of how the clinic itself frames its services. Our scanner flags this pattern and suggests either generalized satisfaction language or removal. Acceptable testimonial framings discuss patient experience, quality of care, or functional outcomes without disease-specific claims.

### What about educational content explaining what stem cells are?

Genuinely educational content - describing biology, mechanism, research history - is generally fine when clearly separated from your service offerings. Problems arise when educational content is used as marketing for your specific treatments (implying the general science justifies specific treatment claims). Our scanner catches the education-bleeding-into-marketing pattern and suggests structural separation.

### Do regen clinics still need a healthcare marketing attorney?

Yes - this specialty needs attorney involvement more than most. Pathway questions, specific-indication advice, and response to any regulatory contact require counsel. Our scanner handles the volume work; the attorney handles the judgment calls. Most regen clinics using both have counsel review the initial scanner-cleaned version of major assets, then rely on the scanner for day-to-day review.

### Is RegenCompliance affiliated with any specific regen medicine association or supplier?

No. We are an independent compliance software company. We are not affiliated with any specific supplier, association, or regulatory body. Our rule set is built from public enforcement records, not from industry group recommendations.

---

RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt